Chemodex

D-Cycloserine

CHF 48.00
In stock
CDX-D0356-G0011 gCHF 48.00
CDX-D0356-G0055 gCHF 150.00
More Information
Product Details
Synonyms (R)-4-Amino-3-isoxazolidone; D-4-amino-3-isoxazolidone; D-Oxamycin; Seromycin; K300, NJ-21; (+)-Cycloserine; α-Cycloserine; (R)-Cycloserine; NSC 76029; NSC 154851
Product Type Chemical
Properties
Formula

C3H6N2O2

MW 102.09
CAS 68-41-7
RTECS NY2975000
Purity Chemicals ≥98% (TLC)
Appearance White to off-white powder.
Solubility Soluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key DYDCUQKUCUHJBH-UWTATZPHSA-N
Smiles O=C1NOC[C@H]1N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

D-cycloserine (DCS) is an antibiotic, inhibiting cell-wall biosynthesis in bacteria. It is a tuberculostatic agent, that inhibits L-alanine racemase and D-alanine:D-alanine ligase, enzymes essential to peptidoglycan synthesis and bacterial cell wall formation. Formulations containing DCS have been used as second-line agents to treat drug resistant tuberculosis. A reason for limited use of this drug is the neurological side effects it causes, since it is able to penetrate into the central nervous system (CNS). DCS acts as a glutamatergic partial N-methyl-D-aspartate (NMDA) agonist. It selectively binds at the glycine-binding site of the NMDA receptor and enable the opening of the NMDA channel. DCS has the ability to improve memory retention in senescence-accelerated mice which exhibit impaired learning and memory.

Product References

(1) W.F. Hood, et al.; Neurosci. Lett. 98, 91 (1989) | (2) G.B. Watson, et al.; Brain Res. 510, 158 (1990) | (3) J.F. Flood, et al.; Eur. J. Pharmacol. 221, 249 (1992) | (4) H. Baran, et al.; Brain Res. 652, 195 (1994) | (5) Z. Feng & R.G. Barletta; Antimicrob. Agents Chemother. 47, 283 (2003) | (6) J.A. Caminero, et al.; Lancet Infect. Dis. 10, 621 (2010) | (7) W. Hong, et al.; Expert Opin. Ther. Targets 18, 691 (2014) (Review) | (8) S. Schade & W. Paulus; Int. J. Neuropsychopharmacol. 19, pyv102 (2016) (Review)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.